Altogether, these findings support Gal-3 as a potentially relevant therapeutic target to treat patients suffering from SSc and prompted us to engage in a strategy targeting the carbohydrate recognition domain (CRD) of Gal-3, responsible for the interaction with its natural ligands1,30. Here, LGALS3 is linked to systemic sclerosis.